RodgerDMacArthurMD

PubMed

• 12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodefi...
  Taylor C Kress, Priscilla Ajala, Coleton R Jordan, James Mintz, Rodger MacArthur, Simone Kennard, Galina Antonova, Eric J Belin de Chantemèle> ;Vascular Pharmacology. 2024 Feb 28
• 5 citations
  Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV.
  Edgar T Overton, Isabelle R Weir, Markella V Zanni, Stephanie Fischinger, Rodger D MacArthur, Judith A Aberg, Kathleen V Fitch, Michael Frank, Helmut Albrecht, Elliot ...> ;Journal of Acquired Immune Deficiency Syndromes. 2022 Aug 1
• 6 citations
  Adapting Education at the Medical College of Georgia at Augusta University in Response to the COVID-19 Pandemic: the Pandemic Medicine Elective.
  Joseph Antony Elengickal, Amanda Delgado, Shefali Priya Jain, Elena Rae Diller, Catherine E. Valli, Kesar K. Dhillon, Hee K. Lee, Rohitha Baskar, Rodger D. MacArthur> ;Medical Science Educator. 2021 Jan 27
• 2 citations
  Widely Disseminated Cryptococcosis Manifesting in a Previously Undiagnosed Human Immunodeficiency Virus (HIV)-Positive 18-Year-Old
  John C. Howard, Thomas Z. Thompson, Rodger D. MacArthur, Amyn M. Rojiani, Joseph White> ;The American Journal of Case Reports. 2020 Oct 12
• 14 citations
  Infectious Diseases Physicians: Improving and Protecting the Public's Health: Why Equitable Compensation Is Critical.
  Matthew Zahn, Amesh A. Adalja, Paul G. Auwaerter, Paul J. Edelson, Gail R. Hansen, Noreen A. Hynes, Amanda Jezek, Rodger D. MacArthur, Yukari C. Manabe, Colin McGoodwi...> ;Clinical Infectious Diseases. 2019 Jul 2
• 13 citations
  Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and M...
  Álvaro H. Borges, Andreas Lundh, Britta Tendal, John Bartlett, Nathan Clumeck, Dominique Costagliola, Eric S. Daar, Patricia Echeverría, Magnus Gisslén, Tania B. Huedo...> ;Clinical Infectious Diseases. 2016 Jul 15
• 4 citations
  The L33F darunavir resistance mutation acts as a molecular anchor reducing the flexibility of the HIV-1 protease 30s and 80s loops.
  Benjamin D. Kuiper, Bradley J. Keusch, Tamaria G. Dewdney, Poorvi Chordia, Kyla Ross, Joseph S. Brunzelle, Iulia A. Kovari, Rodger D. MacArthur, Hossein Salimnia, Ladi...> ;Biochemistry and Biophysics Reports. 2015 Jul 1
• 2 citations
  The role of mutations at codons 32, 47, 54, and 90 in HIV-1 protease flap dynamics.
  Poorvi Chordia, Tamaria G. Dewdney, Bradley J. Keusch, Benjamin D. Kuiper, Kyla Ross, Iulia A. Kovari, Rodger D. MacArthur, Hossein Salimnia, Ladislau C. Kovari> ;Discoveries. 2014 Dec 31
• 4 citations
  Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons
  Poorvi Chordia, Rodger D. MacArthur> ;Expert Review of Gastroenterology & Hepatology. 2013 Sep 1
• 45 citations
  Etiology and Pharmacologic Management of Noninfectious Diarrhea in HIV-Infected Individuals in the Highly Active Antiretroviral Therapy Era
  Rodger D. MacArthur, Herbert L. DuPont> ;Clinical Infectious Diseases. 2012 Jun 14
• 27 citations
  Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage ...
  Rodger D. MacArthur, Trevor N. Hawkins, Stephen J. Brown, Anthony LaMarca, Patrick G. Clay, Andrew C. Barrett, Enoch Bortey, Craig Paterson, Pamela L. Golden, William ...> ;HIV Clinical Trials. 2013 Jan 1
• Overview of the XIX international AIDS conference.
  Rodger D. MacArthur> ;Current Infectious Disease Reports. 2013 Feb 1
• 5 citations
  Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients.
  Rodger D. MacArthur> ;Current Infectious Disease Reports. 2011 Feb 1
• 26 citations
  Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada
  Nisha Andany, Janet Raboud, Sharon Walmsley, Christina Diong, Sean B. Rourke, Sergio Rueda, Anita Rachlis, Wendy Wobeser, Rodger D. MacArthur, Louise Binder, Ron Rosen...> ;HIV Clinical Trials. 2011 Jan 1
• 3 citations
  Instantaneous Inhibitory Potential and Inhibitory Quotient Show a Modest Association with Virologic Outcome: Is Either a Useful Surrogate for Clinical Drug Efficacy?
  Rodger D. MacArthur> ;Clinical Infectious Diseases. 2010 Jul 1
• 31 citations
  Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.
  Thomas P. Giordano, Glenn E. Bartsch, Yafeng Zhang, Ellen Tedaldi, Judith Absalon, Sharon B. Mannheimer, Avis J. Thomas, Rodger D. MacArthur> ;AIDS Patient Care and Stds. 2010 May 20
• 10 citations
  Abacavir/lamivudine combination in the treatment of HIV: a review
  Geetha Sivasubramanian, Emmanuel Frempong-Manso, Rodger D. MacArthur> ;Therapeutics and Clinical Risk Management. 2010 Feb 25
• 8 citations
  Profile of etravirine for the treatment of HIV infection.
  Alice Tseng, Rodger D. MacArthur> ;Therapeutics and Clinical Risk Management. 2010 Jan 21
• 49 citations
  Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial.
  Edward M. Gardner, Katherine Huppler Hullsiek, Edward E. Telzak, Shweta Sharma, Grace Peng, William J. Burman, Rodger D. MacArthur, Margaret A. Chesney, Gerald Friedla...> ;AIDS. 2010 Jan 28
• 10 citations
  Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients.
  Rodger D. MacArthur> ;AIDS Reviews. 2009 Oct 1
• 49 citations
  New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and ...
  Christine A. Hughes, Linda Robinson, Alice Tseng, Rodger D. MacArthur> ;Expert Opinion on Pharmacotherapy. 2009 Sep 17
• 321 citations
  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
  Birgitte B. Simen, Jan Fredrik Simons, Katherine Huppler Hullsiek, Richard M. Novak, Rodger D. MacArthur, John D. Baxter, Chunli Huang, Christine Lubeski, Gregory S. T...> ;The Journal of Infectious Diseases. 2009 Mar 1
• 39 citations
  Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as ini...
  Mary van den Berg-Wolf, Katherine Huppler Hullsiek, Grace Peng, Michael J. Kozal, Richard M. Novak, Li Chen, Lawrence R. Crane, Rodger D. MacArthur> ;HIV Clinical Trials. 2008 Sep 1
• 111 citations
  Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases
  Jason V. Baker, Grace Peng, Joshua Rapkin, David Krason, Cavan S. Reilly, Winston Cavert, Donald I. Abrams, Rodger D. MacArthur, Keith Henry, James D. Neaton> ;Journal of Acquired Immune Deficiency Syndromes. 2008 Aug 15
• 139 citations
  Maraviroc: The First of a New Class of Antiretroviral Agents
  Rodger D. MacArthur, Richard M. Novak> ;Clinical Infectious Diseases. 2008 Jul 15
• Join now to see all